Beckman Coulter Upgraded by JP Morgan | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank JP Morgan has upgraded Beckman Coulter's stock to "overweight" from "neutral," due to the firm's long-range earnings forecast.

In mid-December, Beckman Coulter set a preliminary 2010 guidance for adjusted earnings per share of between $4.40 and $4.55, which was just below analysts' consensus estimate of $4.56.

JP Morgan also set a 12-month price target on the stock of $75.

In early Monday trade on the New York Stock Exchange, shares of Beckman Coulter were up around 2 percent at $67.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.